Avastin (bevacizumab) / Roche - LARVOL DELTA

Case Report: Dual checkpoint inhibition with bevacizumab yields dramatic response in synchronous double primary HCC and ICC with lung metastasis. (PubMed, Front Oncol) - "The patient underwent combination immunotherapy with dual immune therapy of nivolumab plus ipilimumab and bevacizumab, achieving complete remission (CR) of pulmonary lesions and partial response (PR) in hepatic lesions. Our study reports the first case that systematic therapy achieved successful conversion therapy in an unresectable sdpHCC-ICC. Combination immunotherapy might represent a promising therapeutic strategy for sdpHCC-ICC, warranting further validation."

Checkpoint inhibition • Journal • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor

Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study. (PubMed, EClinicalMedicine) - P2 | "This work is supported by the Beijing Municipal Science & Technology Commission (No. Z231100007223002)."

Journal • P2 data • Endocrine Cancer • Hematological Disorders • Leukopenia • Neuroendocrine Carcinoma • Neutropenia • Oncology • Solid Tumor

Successful Treatment of Pericardial Drainage and Platinum-Based Chemotherapy in a Case of BRCA-Positive Serous Peritoneal Carcinoma Complicated by Cardiac Tamponade. (PubMed, Cureus) - "Subsequently, she was diagnosed with BRCA1-positive peritoneal carcinoma and was administered carboplatin, paclitaxel, and bevacizumab. We report the first case of effective platinum-based chemotherapy in a patient with BRCA-positive peritoneal cancer complicated by cardiac tamponade. Chemotherapy has advanced dramatically in recent years, and even in cases with complications, such as cardiac tamponade, appropriate treatment can lead to a favorable long-term prognosis."

Journal • Cardiovascular • Oncology • Peritoneal Cancer • BRCA • BRCA1

Trends in Anti-Vascular Endothelial Growth Factor Injections Among Medicare Part B Beneficiaries in 2013-2021 and the Step Therapy Era. (PubMed, J Vitreoretin Dis) - " Aflibercept usage has continued to rise, matched by a decline in bevacizumab usage and a modest decrease in ranibizumab usage. Step therapy has not significantly increased bevacizumab usage on an aggregate level."

Journal • Medicare • Reimbursement • US reimbursement • Ophthalmology

Utidelone plus bevacizumab for the treatment of HER2-positive breast cancer brain metastases (U-BOMB-HER): A multicenter, single-arm phase IIstudy (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Weekly carboplatin and paclitaxel with trastuzumab and pertuzumab (HER2+) or bevacizumab (HER2-) in the neoadjuvant treatment of breast cancer: a phase II trial (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Improving radical resection rates in patients with breast cancer by intraoperative imaging using bevacizumab-IRDye800CW - the MARGIN-2 study (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Breast Cancer • Oncology • Solid Tumor

Long-term survival of patients who received atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma. (PubMed, J Formos Med Assoc) - "Among patients with advanced HCC treated with first-line Atezo-Bev, approximately 30% survived beyond 3 years. The absence of intrahepatic tumors and preserved liver function were predictive of such prolonged survival."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

TAS-102 plus bevacizumab versus TAS-102 alone for metastatic colorectal cancer: a systematic review and meta-analysis. (PubMed, World J Surg Oncol) - "TAS-102 plus bevacizumab showed superior efficacy and acceptable safety over monotherapy, particularly in RAS-mutant patients, prior bevacizumab use, multiple metastases, and poorer performance status."

Journal • Retrospective data • Colorectal Cancer • Hematological Disorders • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia

Does the combination of anticoagulants and angiogenesis inhibitors increase the risk of bleeding in cancer patients? (PubMed, Thromb Haemost) - "Conclusions Adding anticoagulation to high-dose bevacizumab or antiangiogenic TKIs might increase bleeding risk compared to monotherapy. Conversely, anticoagulants appeared to be safe in patients receiving low-dose bevacizumab."

Journal • Oncology

Preoperative Versus Postoperative Chemotherapy With CAPOX Plus Bevacizumab for Resectable Colorectal Liver Metastases: A Randomized Phase II Trial (HiSCO-01). (PubMed, Ann Gastroenterol Surg) - "NCCN and ESMO guidelines recommend up to 6 months of perioperative oxaliplatin-based chemotherapy for patients with resectable colorectal liver metastases (CRLM). This multimodal approach is highly promising for treating resectable CRLM. UMIN Clinical Trial Registry: UMIN000003783."

Journal • P2 data • Colorectal Cancer • Oncology • Solid Tumor

Case Report: Extended survival in KRAS-G12V NSCLC with leptomeningeal metastasis through integrated intrathecal chemotherapy and systemic therapies. (PubMed, Front Pharmacol) - "Treatment with intrathecal pemetrexed via the Ommaya reservoir, combined with intravenous tislelizumab and carboplatin, resulted in 12 months of progression-free survival. For subsequent central nervous system progression involving both brain parenchymal metastasis and LM, we administered whole brain radiotherapy followed by second-line intrathecal thiotepa via Ommaya reservoir alongside tislelizumab and bevacizumab...Remarkably, the patient has survived nearly 29 months while maintaining good performance status and quality of life - to our knowledge, one of the longest reported survival for an NSCLC patient with LM harboring KRAS-G12V or other non-targetable mutations. This case suggests that combining ventriculoperitoneal shunt with Ommaya reservoir-delivered intrathecal chemotherapy may represent an effective therapeutic approach for LM patients."

Journal • Hematological Disorders • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • KRAS

A novel dual-effect bimodal chip cancer research platform: Chips system interconnected vascularized tumor organoids culture with real-time exploration and detection from bench to bedside. (PubMed, Cancer Lett) - "We demonstrated the platform's capabilities using cervical cancer organoids and evaluated the drug efficacy of cisplatin and bevacizumab. This coupled system enables simultaneous tumor microenvironment modeling and continuous, real-time monitoring of secreted biomarkers, a capability not achievable with conventional disconnected systems. By combining these two systems, our dual-effect bimodal chip platform holds great promise for advancing personalized medicine and cancer research, offering a powerful tool for both drug screening and quick diagnosis."

Journal • Cervical Cancer • Oncology • Solid Tumor

EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: AstraZeneca | N=100 ➔ 60

Enrollment change • Hepatocellular Cancer • Oncology • Solid Tumor

LOXO-FRA-24001: A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=495 | Recruiting | Sponsor: Eli Lilly and Company | N=360 ➔ 495

Enrollment change • First-in-human • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Hormone Receptor Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer • Uterine Cancer

RAINFOL-04: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy (clinicaltrials.gov) - P3 | N=528 | Not yet recruiting | Sponsor: Genmab

New P3 trial • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

GLOBAL PHASE II STUDY OF RISOVALISIB, A SELECTIVE PI3Kα INHIBITOR, AS MONOTHERAPY IN PATIENTS WITH RECURRENT/PERSISTENT OVARIAN CLEAR CELL CARCINOMA HARBORING PIK3CA HOTSPOT MUTATIONS (IGCS 2025) - P2 | "Introduction: Recurrent or persistent ovarian clear cell carcinoma (OCCC) is rare and chemo resistant (ORR <8%). As of July 31, 2024, a total of 93 female patients (China 44.1%, Japan 55.9%) were enrolled; median age 49.0 years. All patients had prior systemic platinum-based chemotherapy; 67.7% received ≥2 lines of systemic therapy. Bevacizumab was used by 69.9% of patients."

Clinical • Late-breaking abstract • Monotherapy • P2 data • Clear Cell Carcinoma • Oncology • Ovarian Cancer • PIK3CA

Utilizing Minimal Physiologically Based Pharmacokinetic Modeling to Bridge Bevacizumab Pharmacokinetics from Adult to Pediatric Patients. (PubMed, AAPS J) - "Overall, the PBPK model successfully bridges the bevacizumab PK from adult to pediatric patients by incorporating age-dependent physiological changes. This work represents a significant step forward in advancing the application of PBPK modeling of mAbs in children."

Journal • PK/PD data • Oncology • Pediatrics

Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study. (PubMed, PLoS One) - "The patients received either biweekly oxaliplatin and 5-fluorouracil through hepatic artery infusion chemotherapy as well as bevacizumab and leucovorin injected intravenously (HAIC-FOLFOX-B) or biweekly irinotecan and 5-fluorouracil by hepatic artery infusion chemotherapy and bevacizumab and leucovorin injected intravenously (HAIC-FOLFIRI-B). HAIC-FOLFOX-B and HAIC-FOLFIRI-B might improve survival in patients with unresectable colorectal liver metastases and in those who underwent both systemic oxaliplatin-based and irinotecan-based chemotherapies and were refractory to them. HAIC FOLFOX-B and FOLFIRI-B regimens might be effective therapeutic options in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy."

Journal • Retrospective data • Infectious Disease • Oncology

Multidisciplinary Treatment for Cecal Cancer and Metachronous Liver Metastases in a Patient with Primary Autoimmune Neutropenia. (PubMed, Surg Case Rep) - "The administration of G-CSF to prevent neutropenia allowed the patient with AIN to safely undergo multidisciplinary treatment."

Journal • Colorectal Cancer • Febrile Neutropenia • Hematological Disorders • Immunology • Infectious Disease • Neutropenia • Oncology • Pain • Rare Diseases • Solid Tumor • HER-2

Systemic avastin as a treatment option for RRP patients. (IPVC 2025) - No abstract available

Clinical • Pulmonary Disease • Respiratory Diseases

QUANTIFYING BEVACIZUMAB EFFICACY IN RECURRENT RESPIRATORY PAPILLOMATOSIS (IPVC 2025) - "In conclusion, based on the above findings, systemic Bev treatment for RRP is a safe and effective therapeutic approach, though further research is needed. Moreover, the new efficacy evaluation method we developed can significantly aid in studying the effectiveness of Bev treatment for RRP."

Clinical • Hypertension

PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOTOV65/KEYNOTE-B96 STUDY (IGCS 2025) - P3 | "Efficacy results favored the pembrolizumab arm (Table 1). Subsequent anticancer therapies were used by 52.2% and 60.4% in the pembrolizumab and placebo arms, respectively (Table 2). Grade ≥3 treatment-related adverse events occurred in 67.5% vs 55.3%, respectively."

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

Risk-based selection of treatment strategies in hepatocellular carcinoma with macrovascular invasion. (PubMed, Radiother Oncol) - "The proposed MVI risk stratification effectively differentiated prognosis and may guide optimal treatment selection for HCC with MVI. Prospective validation is required to confirm the clinical utility."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

Deglycosylation of VEGF Produced in Pichia pastoris Reduces its in Vitro Binding and Angiogenic Effect. (PubMed, Biotechnol J) - "Recombinant human VEGF165 was expressed in P. pastoris, purified via heparin affinity chromatography, and enzymatically deglycosylated using Endo H. Both glycosylated (yVEGFg) and deglycosylated (yVEGFdg) forms were characterized for their binding to an anti-VEGF antibody, bevacizumab, via ELISA and SPR and evaluated for biological activity using HUVEC proliferation assays...Partially glycosylated VEGF from P. pastoris even surpassed mammalian-expressed VEGF in inducing endothelial proliferation. These findings demonstrate that glycosylation significantly enhances the functional properties of recombinant VEGF produced in P. pastoris, emphasizing the importance of glycosylation control for the development of bioactive VEGF."

Journal • Preclinical • VEGFA